文献速递肝病消化道肿瘤与早癌

肝细胞癌免疫人源化小鼠模型用于人靶点与治疗分析验证

Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.
PubMed 文献 · Hepatology · 2021-01-01

研究建立基于细胞系或患者来源异种移植的皮下及原位肝细胞癌(HCC)人源化免疫系统小鼠模型,发现HCC塑造肿瘤微环境中人免疫细胞并激活IL-6/JAK2/STAT3通路,且C188-9、贝伐珠单抗与帕博利珠单抗三联治疗的抗HCC效果优于单药或双药。

要点

  • HCC人源化免疫小鼠模型可用于鉴定肿瘤与免疫细胞靶点并测试联合治疗。
  • 肿瘤内hCD14+细胞经DAMP/TLR4/AP-1产生IL-33,上调IL-6并激活HCC的JAK2/STAT3。
  • C188-9、贝伐珠单抗与帕博利珠单抗三联疗法的抗HCC效果优于单药或双药治疗。

核心结论

  • 人源化免疫系统HCC小鼠模型适合从肿瘤和免疫组分中鉴定靶点并测试联合治疗。

研究设计与样本

  • 建立基于细胞系或患者来源异种移植的皮下及原位HCC人源化免疫系统小鼠模型。
  • 向小鼠注射人特异性抗体以清除人免疫细胞。
  • 使用实时PCR和RNA测序分析HCC细胞与人免疫细胞的转录谱。
  • 使用流式细胞术、蛋白质印迹和免疫组化检测HCC肿瘤细胞/组织或人免疫细胞的蛋白水平。
  • 在单药、双药联合和三药联合治疗后测量HCC肿瘤大小。

主要发现

  • HCC强烈选择并调控肿瘤微环境中的人免疫细胞,促进肿瘤细胞IL-6/JAK2/STAT3信号通路激活。
  • 上述通路激活通过释放血管生成细胞因子增强人源化免疫系统HCC小鼠中的HCC增殖和血管生成。
  • 肿瘤内hCD14+细胞可通过DAMP/TLR4/AP-1产生IL-33,上调其他肿瘤内免疫细胞的IL-6并激活HCC的JAK2/STAT3通路。
  • 在人单核细胞中特异性敲低CD14基因可削弱细胞裂解物诱导的IL-33产生。
  • C188-9、贝伐珠单抗和帕博利珠单抗三联治疗的抗HCC效果优于单药或双药治疗。

临床怎么用

  • 该人源化免疫系统HCC小鼠模型可用于临床前评估从肿瘤和免疫组分中鉴定的靶点及联合治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Recent development of multiple treatments for human hepatocellular carcinoma (HCC) has allowed for the selection of combination therapy to enhance the effectiveness of monotherapy. Optimal selection of therapies is based on both HCC and its microenvironment. Therefore, it is critical to develop and validate preclinical animal models for testing clinical therapeutic solutions. APPROACH AND RESULTS: We established cell line-based or patient-derived xenograft-based humanized-immune-system mouse models with subcutaneous and orthotopic HCC. Mice were injected with human-specific antibodies (Abs) to deplete human immune cells. We analyzed the transcription profiles of HCC cells and human immune cells by using real-time PCR and RNA sequencing. The protein level of HCC tumor cells/tissues or human immune cells was determined by using flow cytometry, western blotting, and immunohistochemistry. The HCC tumor size was measured after single, dual-combination, and triple-combination treatment using N-(1',2-Dihydroxy-1,2'-binaphthalen-4'-yl)-4-methoxybenzenesulfonamide (C188-9), bevacizumab, and pembrolizumab. In this study, human immune cells in the tumor microenvironment were strongly selected and modulated by HCC, which promoted the activation of the IL-6/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in tumor cells and led to augmented HCC proliferation and angiogenesis by releasing angiogenic cytokines in humanized-immune-system mice with HCC. In particular, intratumor human cluster of differentiation-positive (hCD14+ ) cells could produce IL-33 through damage-associated molecular pattern/Toll-like receptor 4/activator protein 1, which up-regulated IL-6 in other intratumor immune cells and activated the JAK2/STAT3 pathway in HCC. Specific knockdown of the CD14 gene in human monocytes could impair IL-33 production induced by cell lysates. Subsequently, we evaluated the in vivo anti-HCC effect of C188-9, bevacizumab, and pembrolizumab. The results showed that the anti-HCC effect of triple-combination therapy was superior to that of single or dual treatments. CONCLUSIONS: Humanized-immune-system HCC mouse models are suitable for identifying targets from cancer and immune components and for testing combinational therapies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Wang J, Liu WN, et al. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model. Hepatology. 2021. PMID: 33738839. doi:10.1002/hep.31812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。